Fulgent Genetics Inc (NASDAQ:FLGT) shares were up 5% during mid-day trading on Wednesday . The company traded as high as $14.20 and last traded at $14.05, approximately 286,785 shares traded hands during mid-day trading. An increase of 1% from the average daily volume of 284,868 shares. The stock had previously closed at $13.38.

A number of analysts have issued reports on FLGT shares. Zacks Investment Research raised Fulgent Genetics from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Tuesday. BidaskClub raised Fulgent Genetics from a “sell” rating to a “hold” rating in a research note on Tuesday. Piper Jaffray Companies raised Fulgent Genetics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $9.50 to $12.30 in a research note on Tuesday, November 5th. Finally, ValuEngine raised Fulgent Genetics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $14.15.

The firm has a market capitalization of $262.88 million, a price-to-earnings ratio of -72.11 and a beta of 1.05. The business has a 50 day simple moving average of $13.04 and a 200-day simple moving average of $10.88. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.22 and a current ratio of 9.22.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.08. The firm had revenue of $10.35 million during the quarter, compared to the consensus estimate of $8.48 million. Fulgent Genetics had a negative return on equity of 0.16% and a negative net margin of 3.52%. Equities analysts predict that Fulgent Genetics Inc will post 0.06 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of Fulgent Genetics by 15.9% during the 2nd quarter. BlackRock Inc. now owns 16,607 shares of the company’s stock worth $111,000 after purchasing an additional 2,281 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Fulgent Genetics during the 3rd quarter valued at about $27,000. Calamos Advisors LLC purchased a new position in Fulgent Genetics during the 4th quarter valued at about $656,000. Wedge Capital Management L L P NC purchased a new position in Fulgent Genetics during the 4th quarter valued at about $1,099,000. Finally, River & Mercantile Asset Management LLP purchased a new position in Fulgent Genetics during the 2nd quarter valued at about $1,034,000. 15.65% of the stock is owned by hedge funds and other institutional investors.

About Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.

See Also: Why are analyst ratings important in trading stocks?

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.